Aditxt (ADTX) versus The Competition Financial Contrast

Aditxt (NASDAQ:ADTX) is one of 248 public companies in the “MED – DRUGS” industry, but how does it weigh in compared to its rivals? We will compare Aditxt to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

15.5% of Aditxt shares are held by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Aditxt and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1	0	0	0	1.00
Aditxt Competitors	2159	3780	9814	408	2.52

As a group, “MED – DRUGS” companies have a potential upside of 60.12%. Given Aditxt’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Aditxt has less favorable growth aspects than its rivals.

Profitability

This table compares Aditxt and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aditxt	-684,001.00%	-461.78%	-80.55%
Aditxt Competitors	-21,296.57%	-156.04%	-17.42%

Valuation & Earnings

This table compares Aditxt and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aditxt	$130,000.00	-$34.45 million	0.00
Aditxt Competitors	$29.76 billion	$56.45 million	3.74

Aditxt’s rivals have higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Aditxt has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Aditxt’s rivals have a beta of -0.70, meaning that their average share price is 170% less volatile than the S&P 500.

Summary

Aditxt rivals beat Aditxt on 12 of the 13 factors compared.

Aditxt Company Profile

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.